1333114-59-2

Basic information

• Product Name: 4-(4-bromobenzyl)-5-((2-methoxyphenyl)sulfonyl)-3,4,5,6-tetrahvdro-1H-benzo-[f][1,4]oxazocine
• Synonyms: 4-(4-bromobenzyl)-5-((2-methoxyphenyl)sulfonyl)-3,4,5,6-tetrahvdro-1H-benzo-[f][1,4]oxazocine
• CAS NO: 1333114-59-2
• Molecular Weight: 502.429
• Mol File: 1333114-59-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(4-bromobenzyl)-5-((2-methoxyphenyl)sulfonyl)-3,4,5,6-tetrahvdro-1H-benzo-[f][1,4]oxazocine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-bromobenzyl)-5-((2-methoxyphenyl)sulfonyl)-3,4,5,6-tetrahvdro-1H-benzo-[f][1,4]oxazocine(1333114-59-2)
• EPA Substance Registry System: 4-(4-bromobenzyl)-5-((2-methoxyphenyl)sulfonyl)-3,4,5,6-tetrahvdro-1H-benzo-[f][1,4]oxazocine(1333114-59-2)

Safety Data

• Hazardous Substances Data: 1333114-59-2(Hazardous Substances Data)

Upstream product

• 1333114-57-0 1-((2-(bromomethyl)benzyl)oxy)-3-(4-bromophenyl)propan-2-amine trifluoroacetate 
• 1333114-55-8 tert-butyl (1-((2-(bromomethyl)benzyl)oxy)-3-(4-bromophenyl)propan-2-yl)carbamate 
• 1333114-54-7 tert-butyl (1-(4-bromophenyl)-3-((2-(hydroxymethyl)benzyl)oxy)propan-2-yl)carbamate 
• 1333114-53-6 methyl 2-((3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propoxy)methyl)-benzoate 
• 1333114-52-5 tert-butyl (1-(4-bromophenyl)-3-hydroxypropan-2-yl)carbamate 
• 89-71-4 2-Methyl-benzoic acid methyl ester 
• 166967-59-5 ethyl 2-amino-3-(4-bromophenyl) propanoate 
• 1333114-58-1 4-(4-bromobenzyl)-3,4,5,6-tetrahydro-1H-benzo[f][1,4]oxazocine 
• 10130-87-7 o-Methoxybenzenesulfonyl chloride 
• 132067-41-5 methyl (±)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 2417-73-4 methyl 2-bromomethylbenzoate 
• 14091-15-7 p-bromo-DL-phenylalanine 
• 118-90-1 ortho-methylbenzoic acid 

Relevant articles and documents

Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease

The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administrating these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides compounds of formula (1) or (2) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.